Examkin

Question

Difficulty: Very hardPharmacologic Interventions

A 62-year-old woman is evaluated in the hospital for new-onset right lower extremity swelling. She was admitted 7 days ago for a non-ST-segment elevation myocardial infarction and has been receiving a continuous intravenous unfractionated heparin infusion. Her vital signs are stable. Physical examination reveals a swollen, erythematous, and tender right calf. Laboratory studies show a platelet count of 95,000/μL95,000/\mu L (down from 260,000/μL260,000/\mu L on admission). A lower extremity venous duplex ultrasound confirms an acute deep vein thrombosis in the right popliteal vein. Heparin-induced thrombocytopenia is highly suspected. Arrange the following pharmacologic management steps in the correct chronological sequence to appropriately treat this patient and safely transition her to long-term outpatient anticoagulation.

  1. 1Discontinue the unfractionated heparin infusion
  2. 2Initiate a continuous argatroban infusion
  3. 3Verify platelet count recovery to ≥150,000/μL\geq 150,000/\mu L and initiate oral warfarin
  4. 4Document a therapeutic INR for at least two consecutive days
  5. 5Discontinue the argatroban infusion

Answer

The correct chronological sequence is: 1) Discontinue the unfractionated heparin infusion, 2) Initiate a continuous argatroban infusion, 3) Verify platelet count recovery to ≥150,000/μL\geq 150,000/\mu L and initiate oral warfarin, 4) Document a therapeutic INR for at least two consecutive days, and 5) Discontinue the argatroban infusion.
The precise chronological management of Heparin-Induced Thrombocytopenia (HIT) requires stopping the offending agent (heparin), immediately securing the patient with a non-heparin parenteral anticoagulant (argatroban) due to the high thrombotic risk, waiting for evidence that the acute phase has resolved (platelet recovery) before introducing a Vitamin K antagonist (warfarin), maintaining a prolonged overlap to ensure full Factor II depletion, and finally ceasing the parenteral bridge.

Step-by-Step Solution

1
Halt the inciting agent.
Discontinue unfractionated heparin.
Heparin exposure drives the formation of IgG antibodies against platelet factor 4 (PF4)-heparin complexes, perpetuating the hypercoagulable state.
2
Establish immediate alternative anticoagulation.
Initiate an intravenous direct thrombin inhibitor (argatroban).
Patients with HIT have an extremely high risk of progressive thrombosis. Stopping heparin alone is insufficient; rapid-acting non-heparin anticoagulation is mandatory.
3
Delay warfarin until the prothrombotic state resolves.
Wait for platelet recovery (≥150,000/μL\geq 150,000/\mu L) before starting warfarin.
Early warfarin initiation causes a precipitous drop in Protein C (a natural anticoagulant), which can lead to microvascular thrombosis and venous limb gangrene in the setting of acute HIT.
4
Overlap therapies (bridge therapy).
Overlap argatroban and warfarin until the INR is therapeutic for 48 hours.
Warfarin takes several days to deplete prothrombin (Factor II). Adequate overlap ensures the patient remains anticoagulated during this transition phase.
5
Remove the intravenous bridge.
Discontinue argatroban.
Once stable warfarin efficacy is confirmed via a therapeutic INR over two consecutive days, intravenous support is no longer needed.

Key Concept

Chronological pharmacologic management of Heparin-Induced Thrombocytopenia (HIT) with thrombosis
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic